CoChat

The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy—clinical effectiveness and safety until 2 years after delivery, with economic evaluation.

Open access
Cooper, Sue, Lewis, Sarah, Thornton, James G, Marlow, Neil, Watts, Kim, Britton, John, Grainge, Matthew J, Taggar, Jaspal, Essex, Holly, Parrott, Steve, Dickinson, Anne, Whitemore, Rachel, Coleman, Tim, for the Smoking, Nicotine And Pregnancy (SNAP) Trial Team · 2014 · Health Technology Assessment

The DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index.

Abstract

Background: Smoking during pregnancy causes many adverse pregnancy and birth outcomes. Nicotine replacement therapy (NRT) is effective for cessation outside pregnancy but efficacy and safety in pregnancy are unknown. We hypothesised that NRT would increase smoking cessation in pregnancy without adversely affecting infants. Objectives: To compare (1) at delivery, the clinical effectiveness and cost-effectiveness for achieving biochemically validated smoking cessation of NRT patches with placebo patches in pregnancy and (2) in infants at 2 years of age, the effects of maternal NRT patch use with placebo patch use in pregnancy on behaviour, development and disability. Design: Randomised, placebo-controlled, parallel-group trial and economic evaluation with follow-up at 4 weeks after randomisation, delivery and until infants were 2 years old. Randomisation was stratified by centre and a computer-generated sequence was used to allocate participants using a 1 : 1 ratio. Participants, site pharmacies and all study staff were blind to treatment allocation. Setting: Seven antenatal hospitals in the Midlands and north-west England. Participants: Women between 12 and 24 weeks’ gestation who smoked ≥ 10 cigarettes a day before and ≥ 5 during pregnancy, with an exhaled carbon monoxide (CO) reading of ≥ 8 parts per million (p.p.m.). Interventions: NRT patches (15 mg per 16 hours) or matched placebo as an 8-week course issued in two equal batches. A second batch was dispensed at 4 weeks to those abstinent from smoking. Main outcome measures: Participants: self-reported, prolonged abstinence from smoking between a quit date and childbirth, validated at delivery by CO measurement and/or salivary cotinine (COT) (primary outcome). Infants, at 2 years: absence of impairment, defined as no disability or problems with behaviour and development. Economic: cost per ‘quitter’. Results: One thousand and fifty women enrolled (521 NRT, 529 placebo). There were 1010 live singleton births and 12 participants had live twins, while there were 14 fetal deaths and no birth data for 14 participants. Numbers of adverse pregnancy and birth outcomes were similar in trial groups, except for a greater number of caesarean deliveries in the NRT group. Smoking: all participants were included in the intention-to-treat (ITT) analyses; those lost to follow-up (7% for primary outcome) were assumed to be smoking. At 1 month after randomisation, the validated cessation rate was higher in the NRT group {21.3% vs. 11.7%, odds ratio [OR], [95% confidence interval (CI)] for cessation with NRT, 2.05 [1.46 to 2.88]}. At delivery, there was no difference between groups’ smoking cessation rates: 9.4% in the NRT and 7.6% in the placebo group [OR (95% CI), 1.26 (0.82 to 1.96)]. Infants: at 2 years, analyses were based on data from 888 out of 1010 (87.9%) singleton infants (including four postnatal infant deaths) [445/503 (88.5%) NRT, 443/507 (87.4%) placebo] and used multiple imputation. In the NRT group, 72.6% (323/445) had no impairment compared with 65.5% (290/443) in placebo (OR 1.40, 95% CI 1.05 to 1.86). The incremental cost-effectiveness ratio for NRT use was £4156 per quitter (£4926 including twins), but there was substantial uncertainty around these estimates. Conclusions: Nicotine replacement therapy patches had no enduring, significant effect on smoking in pregnancy; however, 2-year-olds born to women who used NRT were more likely to have survived without any developmental impairment. Further studies should investigate the clinical effectiveness and safety of higher doses of NRT. Trial registration: Current Controlled Trials ISRCTN07249128. Funding: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 18, No. 54. See the NIHR Journals Library programme website for further project information.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3310/hta18540

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Trial flow from recruitment to delivery.
FIGURE 1 Trial flow from recruitment to delivery.CC-BY · From the PDF
FIGURE 2 Trial follow-up from delivery to infants ' second birthdays.
FIGURE 2 Trial follow-up from delivery to infants ' second birthdays.CC-BY · From the PDF
FIGURE 3 Cumulative trial recruitment.
FIGURE 3 Cumulative trial recruitment.CC-BY · From the PDF
FIGURE 4 The CONSORT diagram showing flow of participants to delivery. From Coleman et al. 56 Copyright © 2012 Massachusetts Medical Society. Reprinted with permission. DNA, did not attend.
FIGURE 4 The CONSORT diagram showing flow of participants to delivery. From Coleman et al. 56 Copyright © 2012 Massachusetts Medical Society. Reprinted with permission. DNA, did not attend.CC-BY · From the PDF
FIGURE 6 The CONSORT diagram showing flow of all trial participants during the 2-year follow-up period. a, 26 HPQs were returned in participants who had already returned a PQ2 ( n = 12 NRT, n = 14 placebo) and these were not included in subsequent analyses. Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind, placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/S2213-2600(14)70157-2.
FIGURE 6 The CONSORT diagram showing flow of all trial participants during the 2-year follow-up period. a, 26 HPQs were returned in participants who had already returned a PQ2 ( n = 12 NRT, n = 14 placebo) and these were not included in subsequent analyses. Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind, placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/S2213-2600(14)70157-2.CC-BY · From the PDF
FIGURE 7 The CONSORT diagram showing flow of participants with live singleton births. These data were used for birth outcome analyses during the 2-year follow-up period. a, 26 HPQs were returned in participants who had already returned a PQ2 ( n = 12 NRT, n = 14 placebo) and these were not included in subsequent analyses. Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind, placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/S2213-2600(14)70157-2.
FIGURE 7 The CONSORT diagram showing flow of participants with live singleton births. These data were used for birth outcome analyses during the 2-year follow-up period. a, 26 HPQs were returned in participants who had already returned a PQ2 ( n = 12 NRT, n = 14 placebo) and these were not included in subsequent analyses. Reproduced with permission. Cooper S, Taggar J, Lewis S, Marlow N, Dickinson A, Whitemore R, et al. Effect of nicotine patches in pregnancy on infant and maternal outcomes at 2 years: follow-up from the randomised, double-blind, placebo-controlled SNAP trial [published online ahead of print 11 August 2014]. Lancet Respir Med 2014. doi:10.1016/S2213-2600(14)70157-2.CC-BY · From the PDF
FIGURE 8 Numbers of questionnaires sent and returned during the follow-up period.
FIGURE 8 Numbers of questionnaires sent and returned during the follow-up period.CC-BY · From the PDF
Image 8
CC-BY · From the PDF
Image 9
CC-BY · From the PDF
Image 10
CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 43

  1. 4. Bowker KA, Lewis S, Coleman T, Vaz LR, Cooper S. Comparison of cotinine levels in pregnant women whilst smoking and when using nicotine replacement therapy. Nicotine Tob Res 2014;16:895-8.
  2. 5. Coleman T, Cooper S, Thornton JG, Grainge MJ, Watts K, Britton J, Lewis S. A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med 2012;366:808-18.
  3. 6. Coleman T, Thornton J, Britton J, Lewis S, Watts K, Coughtrie MWH, et al. Protocol for the smoking, nicotine and pregnancy (SNAP) trial: double-blind, placebo-randomised, controlled trial of nicotine replacement therapy in pregnancy. BMC Health Serv Res 2007;7:2.
  4. 8. Kwok TC, Taggar J, Cooper S, Lewis S, Coleman T. Nicotine dependence and biochemical exposure measures in the second trimester of pregnancy. Nicotine Tob Res 2014;16:145-54.
  5. 10. Royal College of Physicians. Smoking and the Young. London: Royal College of Physicians; 1992.
  6. 18. Martinez-Frias ML, Rodriguez-Pinilla E, Bermejo E. Tobacco smoking during pregnancy in Spain: an analysis according to years, autonomous communities and maternal characteristics. Med Clin (Barc) 2005;124:86-92.
  7. 21. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008 -the MPOWER Package. Geneva: World Health Organization; 2008.
  8. 99. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000;55:987-99.
  9. 100. Dempsey DA,.Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf 2001;24:277-322.
  10. 102. Fiore MC, Hatsukami DK, Baker TB. Effective tobacco dependence treatment. JAMA 2002;288:1768-71.
  11. 103. Wisborg K, Henriksen TB, Jespersen LB, Secher NJ. Nicotine patches for pregnant smokers: a randomized controlled study. Obstetrics & Gynecology 2000;96:967-71.
  12. 104. Kapur B, Hackman R, Selby P, Klein J, Koren G. Randomized, double-blind, placebo- controlled trial of nicotine replacement therapy in pregnancy. Current Therapeutic Research, Clinical & Experimental 2001;62:274-8.
  13. 105. Hegaard HK, KjAErgaard H, MOller LF, Wachmann H, Ottesen B. Multimodal intervention raises smoking cessation rate during pregnancy. Acta Obstetricia et Gynecologica Scandinavica 2003;82:813-9.
  14. 106. Dempsey D, Jacob P, III, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. Journal of Pharmacology & Experimental Therapeutics 2002;301:594-8.
  15. 108. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research 2002;4:149-59.
  16. 109. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine & Tobacco Research 2003;5:13-25.
  17. 110. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-41.
  18. 111. Thomas MG. Frequent wheeze at follow up of very preterm infants: which factors are predictive? Archives of Disease in Childhood: Fetal & Neonatal Edition 2003;88:F329-F332.
  19. 112. Johnson S, Marlow N, Wolke D, Davidson L, Marston L, O'Hare A et al. Validation of a parent report measure of cognitive development for very preterm infants. Developmental Medicine and Child Neurology 2004;46:389-97.
  20. 113. McColl E, Jacoby A, Thomas L, Soutter J, Bamford C, Steen N et al. Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients. Health Technology Assessment (Winchester, England) 2001;5:1-256.
  21. 114. Neonatal Perinatal Epidemiology Unit and Oxford Health Authority. Report of two working groups. Disability and perinatal care: measurement of health status at two years. 1995. Oxford.
  22. 115. Jones HP, Guildea ZE, Stewart JH, Cartlidge PH. The Health Status Questionnaire: achieving concordance with published disability criteria. Archives of Disease in Childhood 2002;86:15-20.
  23. 116. Marlow N. Pulmonary outcomes for the extremely preterm infant. Biology of the Neonate 2000;78:239-40.
  24. 117. Coleman T, Stevenson K, Wilson A. A new method for describing smokers' consulting behaviours which indicate their motivation to stop smoking: an exploration of validity and reliability. Fam.Pract. 2002;19:154-60.
  25. 118. Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. British Journal of Addiction 1989;84:791-9.
  26. 120. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation (Cochrane Review). The Cochrane Library, Issue 4, Chichester, UK: John Wiley & Sons, Ltd, 2003.
  27. 122. Windsor RA, Lowe JB, Perkins LL, Smith-Yoder D, Artz L, Crawford M et al. Health education for pregnant smokers: its behavioral impact and cost benefit. American Journal of Public Health 1993;83:201-6.
  28. 123. Orme ME, Hogue SL, Kennedy LM, Paine AC, Godfrey C. Development of the health and economic consequences of smoking interactive model. Tobacco Control 2001;10:55-61.
  29. 124. Squires J, Bricker D, Potter L. Revision of a Parent-Completed Developmental Screening Tool: Ages and Stages Questionnaires. Journal of Pediatric Psychology 1997;22(3):313-328.
  30. 44. Health Development Agency Expert Panel. Standard for Training in Smoking Cessation Treatments. London: Health Development Agency; 2003.
  31. 52. Squires J and Bricker D. Ages and Stages Questionnaire: A Parent-Completed Child-Monitoring System. 3rd edn. Baltimore, MD: Paul H Brookes Publishing Co.; 2009.
  32. 53. Squires J, Twombly E, Bricker D, Potter L. ASQ-3 User's Guide for the Ages and Stages Questionnaires. 3rd edn. Baltimore, MD: Paul H Brookes Publishing Co.; 2009.
  33. 54. Report of Two Working Groups. Disability and Perinatal Care: Measurement of Health Status at Two Years. Oxford, England: National Perinatal Epidemiology Unit and Oxford Health Authority; 1995.
  34. 56. Marlow N. Pulmonary outcomes for the extremely preterm infant. Biol Neonate 2000;78:239-40.
  35. 62. Anonymous. Handling missing data in randomised trials. Short course 14-15 March 2012. Cambridge: MRC Biostatistics Unit; 2012.
  36. 71. Curtis L. Unit Costs of Health and Social Care 2012. Canterbury: Personal Social Services Research Unit; 2012.
  37. 72. The Health and Social Care Information Centre. Prescription Cost Analysis England 2009. Leeds: The Health and Social Care Information Centre, Prescribing Support Unit; 2010.
  38. 73. Anonymous. NHS Monthly Remuneration Statistics. London: Pharmaceutical Services Negotiating Committee; 2013. URL: http://archive.psnc.org.uk/pages/archive.html (accessed 16 April 2014).
  39. 74. The NHS Staff Council. NHS Terms and Conditions of Service Handbook: Pay Circulars (AforC) 1 and 2/2013, Amendment Number 28. London: The NHS Staff Council; 2013.
  40. 2010, Hospital Episode Statistics, Admitted Patient Care – England, 2009–10
  41. 94. Charlton A. Children and smoking: the family circle. British Medical Bulletin 1996;52:90-107.
  42. 95. Batstra L, Hadders-Algra M, Neeleman J. Effect of antenatal exposure to maternal smoking on behavioural problems and academic achievement in childhood: prospective evidence from a Dutch birth cohort. Early Human Development 2003;75:21-33.
  43. 97. Britton J,.Jarvis MJ. Bupropion: a new treatment for smokers. BMJ 2000;321:65-6.

Cited by

See all 109

Metadata

Authors
Cooper, S., Lewis, S., Thornton, J. G., Marlow, N., Watts, K., Britton, J., Grainge, M. J., Taggar, J., Essex, H., Parrott, S., Dickinson, A., Whitemore, R., Coleman, T., & for the Smoking, N. A. P. (. T. T.
Affiliations
  • University of Nottingham (GB)
  • Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, Nottingham, UK
  • University College London (GB)
  • University of York (GB)
Corresponding author
Cooper, Sue
Venue
Health Technology Assessment
Published
2014-08
Volume
18
Issue
54
Pages
1-128
ISSN
  • 1366-5278 (ISSN-L)
  • 2046-4924
OpenAlex
W2072240881
Cited by
103
References
71
Citations by year
2026: 1 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 4 · 2021: 11 · 2020: 29 · 2019: 5 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 10 · 2014: 2
FWCI
6.89
Type
journal article
Language
en
Open access
Locations
  • Health Technology Assessment (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DMU Open Research Archive (De Montfort University) (submittedVersion, cc-by-nc)
  • Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, other-oa)
Funders
National Institute for Health Research (06/07/01)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
nicotine replacement therapy, pregnancy, smoking cessation, nicotine patch, infant development, infant behavior, infant disability, birth outcomes, cesarean section, cost-effectiveness, maternal smoking, exhaled carbon monoxide, salivary cotinine, adverse pregnancy outcomes, economic evaluation
MeSH terms
Smoking Prevention, Administration, Cutaneous, Adult, Child, Preschool, Cost-Benefit Analysis, Double-Blind Method, England, Female, Humans, Infant, Infant, Newborn, Nicotine, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Smoking, Time, Smoking Cessation, Outcome Assessment, Health Care, Tobacco Use Cessation Devices

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.